We previously reported that in CHD patients common HFE mutations that alter hepatic iron sensing[13] were associated with lower hepcidin levels relatively to iron stores[6,14], achievement of target Hb levels for lower doses of iron, and with reduced mortality due to sepsis and cardiovascular disease, previously linked to more intense iron supplementation[15-18]. The gene discussed is GSTM1; the disease is coronary artery disorder.